Clinical Trials Logo

Filter by:
NCT ID: NCT05572463 Withdrawn - Clinical trials for Metastatic Cutaneous Melanoma

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in participants who have failed standard treatment.

NCT ID: NCT05571111 Withdrawn - Infertility Clinical Trials

Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

TIFFANY
Start date: October 4, 2022
Phase: Phase 2
Study type: Interventional

The primary purpose of this trial is to compare three different doses of FE 999302 with 250 µg OVITRELLE and 10,000 IU NOVAREL on oocyte maturity when administered as a single dose for final development of the oocytes in women undergoing controlled ovarian stimulation.

NCT ID: NCT05557266 Withdrawn - Clinical trials for Mental Health Wellness

Two Recovery Strategies at Work, Based on Mindfulness and Physical Exercise, on Levels of Stress and Biological Measures

ERME2
Start date: March 2023
Phase: N/A
Study type: Interventional

The present study aims to compare the differential effects of mindfulness meditation (MBI) and physical exercise (PE) on different stress and health variables (self-report means and IgA and cortisol levels). A randomized controlled trial of three groups is proposed, with pretest, posttest and three follow-ups at 1, 3 and 6 months that would be developed among the Guardia Civil (Spanish military police) office staff.

NCT ID: NCT05550519 Withdrawn - Clinical trials for Hepatitis B, Chronic

A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment

SALMONS
Start date: October 31, 2022
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to assess the incidence of participants who reach hepatitis B surface antigen (HBsAg) seroclearance after discontinuing nucleos(t)ide analog (NA) therapy in participants with HBsAg less than or equal to (<=) 100 international units per milliliter (IU/mL) and participants with HBsAg greater than (>) 100 IU/mL to <= 500 IU/mL at baseline.

NCT ID: NCT05496192 Withdrawn - Melanoma Clinical Trials

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Start date: May 31, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the switch from Nivolumab Intravenous (IV) infusions to Nivolumab Subcutaneous (SC) administration in participants with resected Stage IIIA/B/C/D or Stage IV melanoma or resected invasive Urothelial Carcinoma (UC) originating in the bladder who have high risk of recurrence.

NCT ID: NCT05281250 Withdrawn - Cancer Patients Clinical Trials

Evaluation of Physical Exercise to Prevent Functional Deterioration During Hospitalization (EFFAPRO)

EFFAPRO
Start date: August 28, 2018
Phase: N/A
Study type: Interventional

This is a randomized study that will measure the possible benefit of supervised training during the hospitalization of patients with stage IV neoplasms in active treatment.

NCT ID: NCT05233410 Withdrawn - Clinical trials for Chronic Hand Eczema (CHE)

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2

TRuE-CHE2
Start date: January 31, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

NCT ID: NCT05219864 Withdrawn - Hand Eczema Clinical Trials

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

TRuE-CHE1
Start date: January 31, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement (IGA) of CHE score 3 or 4).

NCT ID: NCT05198700 Withdrawn - Colic Clinical Trials

The Effect of Probiotics on Symptoms of Infantile Colic

PROCOLIN
Start date: February 8, 2022
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the effects of a probiotic formulation on the daily crying patterns of infants. It is hypothesized that participants given the probiotic formulation will show a significant reduction in daily crying duration compared to participants receiving the placebo.

NCT ID: NCT05189834 Withdrawn - Clinical trials for Covert Hepatic Encephalopathy

GELSECTAN® and Covert Hepatic Encephalopathy

GELSECTAN
Start date: March 11, 2022
Phase: N/A
Study type: Interventional

Randomized crossover pilot clinical trial in which 10 cirrhotic patients with covert hepatic encephalopathy (CHE) will be assigned to take GELSECTAN® (TID) or placebo for 30 days. After a washout period of 15 days, the treatment branches will be interchanged. The objective of the trial is to obtain pilot variances to design a phase II trial, in which the efficacy of the treatment will be tested. As an exploratory objective, the efficacy of the product in the treatment of covert hepatic encephalopathy will be analyzed. Main endpoint Improvement in CHE after 30 days of treatment with GELSECTAN®, measured by the Psychometric hepatic encephalopathy score (PHES)